•
Oct 02, 2021

Plexus Q4 2021 Earnings Report

Announced financial results for the fiscal fourth quarter and fiscal year ended October 2, 2021.

Key Takeaways

Plexus Corp. reported Q4 revenue of $843 million and GAAP diluted EPS of $1.16. The company won 38 manufacturing programs during the quarter, representing $251 million in annualized revenue when fully ramped into production. Supply chain shortages and workforce absences resulting from the pandemic impacted revenue.

Fiscal fourth quarter revenue of $843 million, GAAP operating margin of 5.0% and GAAP diluted EPS of $1.16, including $0.23 of stock-based compensation expense

Trailing four quarter wins total $1.0 billion in annualized revenue when fully ramped into production

Purchased $29.3 million of shares at an average price of $88.39 per share under share repurchase programs

Exited fiscal 2021 with trailing four-quarter wins of $1.03 billion, an increase of 8% year-over-year

Total Revenue
$843M
Previous year: $913M
-7.7%
EPS
$1.16
Previous year: $1.26
-7.9%
Economic Return
7.3%
Previous year: 5.2%
+40.4%
Gross Profit
$79M
Previous year: $89.2M
-11.5%
Cash and Equivalents
$270M
Previous year: $386M
-30.0%
Free Cash Flow
-$11.7M
Previous year: $109M
-110.7%
Total Assets
$2.46B
Previous year: $2.29B
+7.5%

Plexus

Plexus

Forward Guidance

Plexus is guiding fiscal first quarter revenue of $825 to $865 million, GAAP operating margin of 4.6% to 5.0% and GAAP diluted EPS of $1.01 to $1.17. Guidance assumes supply chain constraints and COVID-19 do not further materially impact end markets or operations.

Positive Outlook

  • Customer demand remains robust as a result of improved end markets
  • New program wins
  • Participation in secular growth markets
  • Continued solid operating performance
  • Achieve quarterly sequential revenue growth

Challenges Ahead

  • Constrained component market
  • Supply chain constraints are a limiting factor in our ability to fulfill all the available demand
  • COVID-19, including potential vaccination and testing mandates
  • Supply chain constraints
  • COVID-19